-- Highly complementary transaction will strengthen company's ability to 
support bioanalytical services across all stages, development capabilities and 
geographies

BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research 
laboratory focused on supporting its pharmaceutical and biotech partners in all 
stages of large molecule drug development, announced today that it signed a 
definitive agreement to purchase 360biolabs(R), the most comprehensive contract 
research organization in Australia. The transaction will expand BioAgilytix's 
global footprint into a jurisdiction of choice to commence first-in-human 
trials (FIH) and early-phase clinical trials and adds further capacity by 
joining 360biolabs' internationally recognised Quality systems (ISO/IEC 17025, 
ISO 15189, GLP and GCLP) in Melbourne, Victoria with BioAgilytix's existing 
laboratories in Durham, North Carolina; Boston, Massachusetts; and Hamburg, 
Germany.

Photo - https://mma.prnewswire.com/media/1594905/360biolabs.jpg
Logo - https://mma.prnewswire.com/media/1278852/BioAgilytix_Logo.jpg

Located in Australia's biomedical and clinical research hub, 360biolabs offers 
world-class virology and immunology expertise, with BSL 2 and 3 laboratories, 
biomarker and immune monitoring capabilities with a state-of-the-art flow 
cytometry suite, molecular biology PCR suite and expansive bioanalytical 
LC-MS/MS small molecule capabilities.

"This planned acquisition is part of our strategic growth strategy to expand 
our capacity, expertise and agility to serve customers across all geographies, 
and we look forward to welcoming the 360biolabs team and integrating the 
business," said Jim Datin, President and CEO of BioAgilytix. "Joining forces 
makes sense for our two organizations, but most importantly for our combined 
clients and the patients they serve. BioAgilytix and 360biolabs are already 
culturally aligned in our focus on doing science right, on time, the first 
time. Together, we will not only create significant scientific synergies but 
also generate new innovations and help bring future life-changing therapeutics 
to patients more rapidly around the globe."   

"From the launch of 360biolabs in 2015, our strategic vision was to build a 
global speciality laboratory, providing support to enable future medicines for 
human health," said Angela Luttick, 360biolabs Cofounder and Executive Vice 
President, Business Development. Added 360biolabs Cofounder and CEO Alistair 
Draffan, "Finding a like-minded partner, driven by a team-focused culture of 
excellence with an international reputation, US and European presence, will 
drive our strategic expansion and support our clients' clinical development 
programs." Melinda Pryor, Cofounder and Executive Vice President, Clinical 
stated, "We're excited to join forces with the BioAgilytix team, a company that 
shares our strong scientific track record and commitment to quality and 
service. Together, we have the capabilities and capacity to meet all 
challenges, especially in this time of pandemic, and create enduring 
opportunities for a brighter future."

The Burnet Institute, a global medical research and public health organisation, 
is a Cofounder and majority shareholder of 360biolabs. Burnet Institute 
Director and CEO, Professor Brendan Crabb AC said, "Burnet Institute is proud 
of its involvement in the foundation of 360biolabs. It is the right time, with 
the growing need for high quality clinical trial support, for a company of the 
scale, capability, and reputation of 360biolabs to join with BioAgilytix and 
expand their capacity to service their customers and facilitate high quality 
translational medical research."

The acquisition is subject to Australian Foreign Investment Review Board 
("FIRB") requirements and, subject to receipt of FIRB approval, is expected to 
close in the third quarter of 2021. BioAgilytix selected White & Case as legal 
counsel to oversee the closing of the acquisition, with Lazard Australia and 
Allens representing 360biolabs.

About BioAgilytix
BioAgilytix is a leading bioanalytical testing laboratory specializing in large 
molecule bioanalysis. With laboratory locations in North Carolina's Research 
Triangle Park, the Cambridge area of Massachusetts, and Hamburg, Germany, 
BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay 
services supporting the development and release testing of biologics across a 
number of industries and disease states.

BioAgilytix offers assay development, validation, and sample analysis under 
non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e., product 
release testing, stability testing, etc.). BioAgilytix also offers diagnostic 
testing services at its CLIA-certified, CAP-accredited Boston laboratory.

BioAgilytix's team of highly experienced scientific and QA professionals 
ensures high-quality science, data integrity and regulatory compliance through 
all phases of clinical development. BioAgilytix is a trusted partner to many 
top global pharmaceutical and biotech companies. For more information, visit 
www.bioagilytix.com.

About 360biolabs(R)
360biolabs(R) is the leading and most comprehensive specialty laboratory in the 
Australia & New Zealand region. Our expert pharmacokinetic (PK) and 
pharmacodynamic (PD) assay services support small molecule, biologic, vaccine 
and other innovative therapeutic solutions to human health. A world class and 
industry experienced technical team, known for their ability to successfully 
deliver technically challenging assays, 360biolabs(R) supports global 
Pharmaceutical and biotech companies in a diverse and growing range of 
therapeutics areas.

360biolabs(R) delivers global regulatory compliant assays and reports following 
ISO/IEC 17025, ISO 15189, OECD GLP, GCLP and ICH GCP with a focus on quality. 
For more information, visit www.360biolabs.com.

Media Contact:
Pam O'Connor
BioAgilytix
+1 919-621-1230
pam.oconnor@bioagilytix.com  


SOURCE: BioAgilytix